FC
CRSP icon

Fairscale Capital’s CRISPR Therapeutics CRSP Stock Holding History

Fairscale Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.81K Hold
59
– – ﹤0.01% 369
2025
Q4 		$3.09K Sell
59
-55
-48% -$3.29K ﹤0.01% 356
2025
Q3 		$7.39K Hold
114
– – 0.01% 343
2025
Q2 		$6.41K Sell
114
-3
-3% -$116 ﹤0.01% 345
2025
Q1 		$3.98K Hold
117
– – ﹤0.01% 279
2024
Q4 		$4.61K Hold
117
– – ﹤0.01% 273
2024
Q3 		$5.5K Sell
117
-91
-44% -$4.62K ﹤0.01% 269
2024
Q2 		$13.1K Buy
+208
New +$12K 0.01% 247

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fairscale Capital's CRSP Position: Q1 2026 in Review

Fairscale Capital held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 59 shares worth $2.81K. The position accounts for ﹤0.01% of the portfolio, ranked #369.

Fairscale Capital first reported a position in CRSP in Q2 2024 and has held it in 8 quarters since. The position peaked at $13.1K in Q2 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Fairscale Capital held 59 shares of CRISPR Therapeutics worth $2.81K as of Q1 2026.
  • Fairscale Capital left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Fairscale Capital's portfolio in Q1 2026, its #369 holding.
  • Fairscale Capital first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Fairscale Capital's CRISPR Therapeutics position peaked at $13.1K in Q2 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Fairscale Capital's 13F filing for Q1 2026, filed 11 May 2026.